The purpose of this study was to investigate the efficacy and feasibility of unmanipulated haploidentical PBSCT for the treatment of acute leukemia (AL). This study compares the clinical outcomes of high-risk AL patients who received PBSCs harvested from family members sharing at least one common haplotype to outcomes of high-risk AL patients who received a mixture of G-CSFprimed BM (G-BM) and peripheral blood (G-PB) harvests. The results show that PBSCT achieved inferior cumulative myeloid engraftment at 30 days after transplant (89.9 ± 10.1% vs 100%; P ¼ 0.04), with lower cumulative incidence of grade II-IV acute GVHD (aGVHD) (37.1 ± 16.5% vs 63.2 ± 6%; P ¼ 0.058) compared with G-BM/G-PB transplant. However, both transplant protocols had similar rates of 2-year relapse (29.6±17.1% vs 34.0±5.7%; P ¼ 0.954), and PBSCT produced a higher incidence of 2-year non-leukemic mortality (62.5 ± 14.8% vs 35.1 ± 5.1%; P ¼ 0.014), as well as lower rates of overall (26.8±12.3% vs 43.2 ± 5.0%; P ¼ 0.052) and disease-free survival (26.8 ± 12.3% vs 42.4 ± 5.0%; P ¼ 0.071) compared with G-BM/G-PB transplant. These results suggest that haploidentical HSCT is an option for patients with AL who urgently need a graft and do not have matched sibling donors. PBSCT is potentially inferior to G-BM/G-PB transplant, and improvements should be made before PBSCT becomes a routine in unmanipulated mismatched/ haploidentical transplant settings.
Introduction
Despite advances in chemotherapy, most patients with acute leukemia (AL) eventually relapse. Few patients survive when they have unfavorable prognostic features at diagnosis, when they are refractory to chemical agents, when they are in second or later CR 1 and when they relapse after autologous hematopoietic SCT (auto-HSCT). Under these circumstances, allo-HSCT is the only therapeutic option and an immediate donor is usually needed for salvage therapy.
Allo-HSCT has traditionally been limited to patients with an HLA-matched sibling, a matched unrelated donor or cord blood. Only 25% of patients have an HLAidentical sibling. Most other patients never find an HLA-matched unrelated donor, or do not have enough time for the search and preparation process, due to disease progression. 2 In addition, umbilical cord blood usually contains insufficient cell doses for adult patients. 3 However, haploidentical donors can be found for almost all patients, with minimal delay between decision-making and transplantation, which is crucial in urgent cases. Therefore, haploidentical transplants can emerge as a viable option when matched donors are unavailable. This will become much more important in the future for the increasing numbers of Chinese patients who are the only child in their family.
Recently, we have successfully established a novel approach for haploidentical transplantation without ex vivo T-cell depletion. In this protocol, patients were conditioned with a modified BU plus CY plus antithymocyte globulin (ATG) regimen, and the mixture of G-CSF-primed BM (G-BM) and G-CSF-primed peripheral blood (G-PB) was used as the source of stem cells. All patients achieved complete donor chimerism. [4] [5] [6] On the other hand, PBSC is becoming popular in the allotransplant setting because of faster engraftment, [7] [8] [9] and recent studies showing durable engraftment using PBSCT even in haploidentical HSCT. 10, 11 Aversa et al. 10 report that using a megadose of CD34 þ cells selected by CliniMacs (Miltenyi Biotech, Bergisch Gladloach, Germany) from G-PB, together with highly immunosuppressive and myeloablative conditioning, resulted in a high incidence of durable engraftment in haploidentical HSCT; the reported engraftment rate is 91%. Rizzieri et al. 11 reported the clinical outcomes in in vitro T-cell-depleted non-myeloablative partially matched/haploidentical PBSCT, with the conditioning of fludarabine plus CY plus alemtuzumab; 94% of 49 patients had successful engraftment. Therefore, we designed an open, prospective trial to test the treatment outcome using PBSCT alone in high-risk leukemia patients undergoing haploidentical transplantation, and compared the results with a historical control group of high-risk leukemia patients receiving combined stem cells using G-CSF-mobilized PB and BM.
Patients and methods

Patient eligibility
Patients were eligible for haploidentical PBSCT if they satisfied all the following criteria: (1) fit for HSCT; (2) no HLA-matched donor or volunteer donor available; (3) high-risk AL; and (4) refusal of BM harvest. Patients with malignancies were categorized as 'standard risk' if they were in the first or second CR (CR1 or CR2) of AL, and lacked the Ph chromosome. Patients were stratified as 'high risk' if they were not in remission, in more than CR2, or in CR1 or CR2 with t(9;22). 6 The Institutional Review Board of Peking University approved this study, and all patients and their donors gave written informed consent. We designed an open, prospective trial to test the clinical outcomes of patients receiving G-PB from haploidentical donors who refused or who were unable to undergo a concomitant BM harvest. Accrual to the G-PB-only study was closed after two cases of graft failure occurred; the clinical outcome of recipients of G-PB is compared with a control group transplanted with the combination of G-BM and G-PB (Figure 1) 2 ) on day À3; and ATG (2.5 mg/kg per day i.v. of rabbit ATG (Sangstat-Genzyme, Cambridge, MA, USA) Sangstat product) on days À5, À4, À3 and À2. The rationale of adding Ara-C and Me-CCNU to the BU/CY/ATG regimen is to increase leukemia cell killing.
Donor selection and stem cell graft harvest HLA-A and HLA-B alleles were determined by lowresolution molecular typing using PCR sequence-specific primers (PCR-SSPs). HLA-DRB1 was determined by highresolution molecular typing using PCR-SSPs. Family donors were ranked on the basis of best HLA match, age (younger preferred), relationship (mother preferred), gender (same preferred) and health status (better preferred). Donors were primed with rhG-CSF (Filgrastim, Kirin, Japan; 5 mg/kg per day) injected s.c. for five to six consecutive days. In the PBSCT group, on the fourth and fifth day (and on the sixth day if needed), PBSCs were collected with a COBE Blood Cell Separator (Spectra LRS, COBE BCT Inc., Lakewood, CO, USA) at a rate of 80 ml/ min from a total blood vol of 150-200 ml/kg. The fresh and unmanipulated PBSCs were infused into the recipient on the day of collection. Surface markers of the cells in the graft were determined by two-or three-color staining using monoclonal Abs specific for CD34 þ , CD3 þ , CD4 þ and CD8 þ cells. In the control group, G-BM was harvested on the fourth day, and PBSCs were collected on the fifth day (and on the sixth day if needed).
GVHD prophylaxis
All transplant recipients received CsA, mycophenolate mofetil (MMF), and short-term MTX. The dosage of CsA was 2.5 mg/kg per day, i.v. from day 9 before transplantation until bowel function returned to normal, and then the patient was switched to oral CsA. MMF was administered orally, 0.5 g every 12 h, from day 9 before transplantation to day 30 after transplantation, and 0.25 g every 12 h from day 31 until day 45 after transplantation. The dosage of MTX was 15 mg/m 2 , administered i.v. on day 1, and 10 mg/m 2 on days 3, 6 and 11 after transplantation. Whole-blood CsA concentration was monitored weekly using fluorescence polarization immunoassay, and the dosage was adjusted to a serum concentration of 150-250 ng/ml. If there was no evidence of GVHD by days 40-50, the CsA dosage was reduced gradually and discontinued around day 90. CsA was continued if GVHD occurred.
Evaluation and monitoring of engraftment, chimerism and MRD
The myeloid cell recovery time was defined as the first of three consecutive days during which the ANC in the blood was at least 0.5 Â 10 9 /l. Plt recovery time was achieved in the first of 7 days when the plt count was 420 Â 10 9 /l without transfusion support. Chimerism was determined by 
DLI
Modified donor lymphocyte infusion (DLI) was performed for the treatment of leukemia recurrence or as a prophylaxis for leukemia relapse in patients with increased MRD following immunosuppressant withdrawal. The modified DLI (mDLI) regimen comprised G-CSF-primed PBSCs instead of harvested non-primed donor lymphocytes and short-term immunosuppressive agents.
12,13
Infection and supportive care All patients were hospitalized in rooms with high-efficiency particle-arresting (HEPA) air filters and received antibiotic prophylaxis with oral trimethoprim-sulfamethoxazole, fluconazole and acyclovir starting at day 10 before transplantation. All blood products were irradiated before infusion. Human Ig (400 mg/kg /l. G-CSF (5 mg/kg per day, s.c.) was administered to all recipients from day 6 after transplantation until myeloid recovery. Blood products were irradiated with 2500 cGy.
Ganciclovir (5 mg/kg) was administered i.v. twice daily from days 10 to 2 before transplantation. Patients were monitored weekly for CMV by DNA (real-time PCR), or CMV pp65 Ag tests. Patients with CMV Ag were treated with either ganciclovir or foscarnet. CMV-related interstitial pneumonia was defined according to the reported criteria. Surveillance for bacterial, fungal and viral infections, including Pneumocystis carinii infection, were based on clinical requirements.
Definitions and end points
Primary engraftment failure was defined as the absence of donor-derived myeloid cells on the day of death, or on the day of relapse in patients surviving beyond 28 days after transplantation. Primary engraftment failure was also defined when a patient required either a second allo-HSCT or reconstitution with autologous cells before achieving donor-derived myeloid stable recovery. 14 Acute GVHD was graded 0-IV according to the criteria of Glucksberg et al., 14 and chronic GVHD (cGVHD) was defined as none, limited or extensive. 15, 16 The incidence of aGVHD was evaluated in patients with evidence of engraftment. The incidence of cGVHD was evaluated in patients surviving X100 days after transplantation with allogeneic engraftment. TRM was defined as death from any cause except relapse.
Relapse was defined by morphological evidence of disease in peripheral blood, marrow or extramedullary sites, or the recurrence and sustained presence of pretransplantation chromosomal abnormalities on cytogenetic analysis of BM cells. Disease-free survival (DFS) was defined as survival in continuous CR. We focused on the end points of hematological recovery, aGVHD, cGVHD, TRM, disease relapse and DFS after haploidentical PBSCT.
Statistics
Distributions of overall survival and DFS were evaluated using Kaplan-Meier analysis. A cumulative incidence test, such as engraftment, aGVHD, cGVHD, relapse or TRM, was used to account for follow-up time and the competing risk of death. The end point of the last follow-up for all surviving patients was 10 April 2009. Unless otherwise specified, all reported P-values were based on two-sided hypothesis tests. Alpha was set at 0.05. A statistical software package (SPSS 13 for Window, Chicago, IL, USA) was used. NCSS software (NCSS, Kaysville, UT, USA) was used to calculate the cumulative incidence considering the presence of competing risk.
Results
Patients' characteristics
All patients in both groups had high-risk AL. 16 A total of 14 patients were included in the PBSCT group; the median age was 32 (range, 8-51 years), 4 were male and 10 were female. Three patients had Ph chromosome-positive myeloid/ lymphoid leukemia; four had refractory or chemoresistant relapsed AL; four had AML secondary to myelodysplastic syndrome in a non-remission or untreated state; two had relapsed after single or double autologous HSCT; and one patient had CML in blast crisis. Characteristics of the patients and donors are summarized in Table 1 .
Donors and stem cell graft characteristics
All donors were HLA-mismatched/haploidentical family members. Three of six HLA loci were identical in eleven donor/recipient pairs; four of six HLA loci were identical in three pairs. One to three leukaphereses were performed in fourteen donors between days 4 and 6. Donors underwent one (n ¼ 1), two (n ¼ 12) or three (n ¼ 1) harvesting procedures. A median of 7.14±1.39 Â 10 8 /kg mononuclear cells (including a median of 2.54 ± 1.22 Â 10 6 /kg CD34 þ cells) was infused to recipients. The infused graft subgroups are shown in Table 1 . The donors reported no untoward effects during or after the administration of rhG-CSF, or from the blood collections. See Table 2 for further details.
Engraftment
Two patients died of sepsis before day 28 after transplantation without myeloid recovery. In all, 10 (93.75%) of 12 assessable patients achieved myeloid engraftment at a median of 12 days (range, 10-20 days). A total of 10 patients with myeloid engraftment had full-donor-type chimerism in peripheral blood and in BM by 30 days after transplant. The cumulative 30-day myeloid engraftment probability was 89.9±10.1% in the PBSCT group and 100% in the control group (P ¼ 0.04). In the PBSCT group, primary graft failure occurred in two patients. One received a second HSCT with G-BM/G-PB from the same donor on day 29 after conditioning with CY (CY 1000 mg per day Â 2 days), fludarabine (Flu, 50 mg per day Â 4 days) and anti-CD25 MoAb. In spite of a peak WBC count of 0.9 Â 10 9 /l on day 32 after the second HSCT, no sustained myeloid engraftment was confirmed until he died of sepsis on day 41 after the second HSCT. The other patient experienced graft failure on day 17 after 2 days of transient ANCs 40.5 Â 10 9 /l. She received G-BM/G-PB cells from the same donor after anti-CD25 MoAb preparation, and achieved sustain engraftment again on day 12 after the second HSCT. Eight patients achieved plt engraftment at a median of 17 days (range, 7-42 days). Four patients did not have plt engraftment at death (on days 23, 26, 60 and 90, respectively). All patients in the control group achieved myeloid engraftment. The 50-day cumulative plt engraftment probability was 79.6±15.9% in the PBSCT group and 86 ± 3.4% in the G-BM/G-PB group (P ¼ 0.41).
GVHD
Among 10 assessable patients, 5 cases experienced no aGVHD, 2 patients had grade I, 2 patients had grade II and 1 patient had grade III-IV. At day 100 after PBSCT, the cumulative incidence of grade II-IV aGVHD was 37.1 ± 16.5% in the PBSCT group and 63.2 ± 6% in the control group (Figure 2 , P ¼ 0.058). The cumulative incidence of III-IV grade GVHD was 12.5±11.7% in the PBSCT group and 21.7±6.2% in the control group (P ¼ 0.559). Acute GVHD of grade II or higher was treated with methylprednisolone (0.5-1 mg/kg per day). Acute GVHD manifesting in the skin was treated with MTX. No patients in the PBSCT group died of aGVHD; one developed cGVHD (skin, extensive). Of nine patients surviving beyond 100 days after PBSCT, five had cGVHD (four limited, one extensive). In all, 50 of 87 patients surviving beyond 100 days in the control group have cGVHD (38 limited, 12 extensive) (Figures 3 and 4) . The 2-year cumulative incidence of cGVHD was 40.0 ± 18.2% in the PBSCT group vs 60.2 ± 6.6% in the control group (P ¼ 0.917), and the respective 2-year cumulative incidence of extensive cGVHD was 12.5±11.7% vs 20.5±5.6% (P ¼ 0.643). Leukemia relapse and follow-up Except for two patients who died before engraftment, all patients had CR after HSCT. Six patients received prophylaxis intervention, four received mDLI and two received imatinib. Two of the six patients relapsed (case no. 6 and 7). Case no. 6 was transplanted for relapsed ALL, and received mDLI on day 51 after PBSCT for prophylaxis of leukemia. The patient experienced central nervous system and lymph node relapse 12 months after PBSCT, and grade II aGVHD occurred. Then, the patient was given chemotherapy followed by mDLI. Grade III-IV aGVHD occurred and the patient died of severe pneumonia on day 435 after the relapsed leukemia disappeared. Case no. 4 received modified DLI for prophylaxis of leukemia on day 34 after PBSCT; grade II aGVHD occurred and was controlled easily. Extensive cGVHD occurred on day 100 after PBSCT and a partial response to CsA, MTX, steroids and azathioprine. A second mDLI was given on day 140 after HSCT due to an increased WT1 level. Leukemia relapsed on day 240 with extensive cGVHD. The patient died of relapse on day 323.
In the PBSCT group, five patients relapsed. The 2-year cumulative incidence estimate of relapse was 29.6±17.1% in the PBSCT group vs 34.0 ± 5.7% in the G-BM/G-PB group (P ¼ 0.954).
In the PBSCT group, twelve patients died, three of leukemia relapsed and nine without relapse. Of the nine patients who died without relapse, two died of infections before day 28 without engraftment, one patient died of severe pneumonia on day 60, one died of primary graft failure followed by severe infection, one died of severe GVHD, one patient died of gastrointestinal bleeding and the other three patients died of infection. The 2-year nonleukemic mortality was 62.5 ± 14.8% in the study group and 35.1 ± 5.1% in the control group ( Figure 5 , P ¼ 0.014).
Only two patients in the PBSCT group survived until the final follow-up. Respective final follow-ups were 550 and 750 days after PBSCT, and both were leukemia free. In all, 51 cases in the control group survived, with a median follow-up of 960 days (range, 147-2291 days). The 2-year probability of overall survival was 26.8 ± 12.3% in the PBSCT group vs 43.2±5.0% in the control group (P ¼ 0.052), and the 2-year probability of DFS was 26.8 ± 12.3% in the PBSCT group vs 42.4 ± 5.0% in the control group (P ¼ 0.071) ( Figure 6 ).
Discussion
In the past several years, a great deal of progress has been made in HLA-mismatched HSCT without T-cell depletion (TCD). The good results of quick engraftment, a relatively low incidence of GVHD and a good GVL effect were reported, and the problem of engraftment has been solved. In our previous report on haploidentical blood and marrow transplantation without in vitro TCD for the treatment of hematological malignancies, all the 171 cases achieved fulldonor chimerism, the median time for myeloid engraftment was 12 days (range, 9-26 days) and for plts 15 days (range, 8-151 days). 6 The combination of G-BM and G-PB harvest was used as the source of stem cells. A median of 1.8 million CD34
þ cells/kg were infused in this protocol. In this study, we extended the protocol to include patients whose donor did not tolerate or was unwilling to donate BM. Mononuclear cell infusion and CD34 þ cell infusion were similar to our previous report. However, 2 of 14 patients experienced primary graft failure, and the 30-day myeloid engraft probability is 89.9 ± 10.1% in the PBSCT group and 100% in the control group (P ¼ 0.04). Compared with the control group, the only change in this study is that a G-PB harvest was used instead of the G-BM/G-PB mixed harvest as the source of stem cells. All patients in the control group achieved successful engraftment. Therefore, the results suggest that the G-PB harvest was inferior to the G-PB/G-BM mixed harvest in terms of engraftment potential. Recently, Rizzieri et al. 11 reported the clinical outcomes of partially matched/haploidentical PBSCT in 49 patients; 94% of 49 patients had successful engraftment and 8% had secondary graft failure. In the protocol of Rizzieri, patients were conditioned with fludarabine/CY/ alemtuzumab and a median of 13.5 million CD34 þ cells/kg were infused, which was much higher than in our study. Our results suggest that different cellular compositions and immunological effects exist between the G-BM/G-PB mixed and G-PB-only harvests. 17, 18 Therefore, it is possible that differences in hematopoietic reconstitution between the G-BM/G-PB mixed and G-PB-only harvests exist, although further study is needed to confirm this.
In HLA-identical HSCT, the incidence of aGVHD was not higher in PBSCT than BMT. HLA-mismatched/ haploidentical family donor HSCT had similar results. Rizzieri et al. 11 reported 16% grade II-IV aGVHD and 11.4% cGVHD in partially matched/haploidentical PBSCT with fludarabine plus CY plus alemtuzumab conditioning, and without in vitro TCD. In our previous report on haploidentical HSCT from G-PB/G-BM without in vitro TCD, 100-day cumulative incidence of grade II-IV aGVHD was 40% (95% confidence interval (CI): 32-48%), and 2-year cumulative incidence of cGVHD was 55% (95% CI: 46-64%). 6 In this trial, the cumulative incidence of grade II-IV aGVHD in the PBSCT group was 37.1 ± 16.5%, and appeared higher than in the control group (63.2±6%) (P ¼ 0.058). This is due to the small size of the control group. However, a higher frequency of aGVHD was indeed expected, as a higher T-cell dose was present in the G-PBSCT group than the control G-PB/BM control group. (Table 3 ) The 2-year cumulative incidence of extensive cGVHD was 12.5 ± 11.7%. Therefore, the incidence of aGVHD and the incidence of extensive cGVHD in this haploidentical PBSCT without TCD were not higher than in G-PB/G-BM HSCT. 0.00 500.00 1000.00 1500.00 2000.00 2500.00 3000.00
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Overall survival Figure 6 Kaplan-Meier estimates of overall survival in patients of PBSCT group (n ¼ 14) vs BM/PB group (n ¼ 109).
